Antiviral defense gained at the cost of autoimmunity risk, study shows
Why do genetic variants that increase the risk of autoimmune disease remain so common in the population?
17 hours ago
0
5
MeSH tree: D12.776.744
Why do genetic variants that increase the risk of autoimmune disease remain so common in the population?
17 hours ago
0
5
Alzheimer's disease is one of the most feared diagnoses among older adults, particularly for those who know they carry a high-risk gene that magnifies their odds. But even many people with this gene—APOE ε4—dodge the disease ...
19 hours ago
0
9
A new study finds that when p53, one of the most important cancer-protecting genes, stops working, cells produce too much RNA and consume excessive amounts of the building blocks needed to copy their DNA. This shortage disrupts ...
Sep 7, 2026
0
12
Researchers at Peter Mac have discovered why breast cancer treatment stops working for some patients, uncovering the unexpected role of one of the body's most important cancer-fighting proteins. The study, published in Nature, ...
Aug 13, 2026
0
20
A new study led by researchers at the University of California San Diego School of Medicine suggests that an experimental gene therapy could help protect the brain from the damage and cognitive decline linked to TDP-43-related ...
May 26, 2026
0
8
The stiffness of tumor tissue plays a role in how cancer spreads. Furthermore, stiff tumor tissue leaves traces in the affected cells, according to two recent research studies from Lund University. "This helps us to better ...
Apr 26, 2026
0
7
Researchers have discovered that a mutation of the MDGA1 gene, a key factor modulating the connections and characteristics between nerve cells, serves as a new cause of autism spectrum disorder (ASD), and suggested the possibility ...
Apr 9, 2026
0
12
Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors. Different forms ...
Mar 5, 2026
0
14
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator designed for tumors with TP53 Y220C, and observed antitumor activity across multiple solid tumor types ...
A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. ...
Feb 12, 2026
0
19